Treatments
544 articles
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.
Research and Other Highlights from the 2023 AACR Annual Meeting
The 2023 AACR meeting focused on the latest research into KRAS, other immunotherapy approaches, and honored Dr. Elizabeth Jaffee.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Meet the Researcher: Arnav Mehta, M.D., Ph.D.
Dr. Arnav Mehta combines mathematics and medicine in his search to improve options for gastrointestinal cancer patients. Learn about his groundbreaking work.
The Cancer Moonshot
Dr. Elizabeth Jaffee of Johns Hopkins is part of the Cancer Moonshot’s Blue Ribbon Panel, and she explains the goals of the program.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Neoantigens Provide New Hope for Pancreatic Cancer Treatments
Vinod Balachandran’s team identified increased T cells in the tumors of long-term pancreatic cancer survivors, with a role for neoantigens in immunotherapy.
Evaluating Different Immunotherapy Combinations
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
Platform Trial Design Aims to Get Information Quickly and Efficiently
Dr. Eugene Koay is leading a platform trial, for a more nimble way to adapt to participants’ response to treatments being tested.
AACR Special Conference Highlights Advances in Pancreatic Cancer Research
Here are some of the most interesting highlights from the 2024 AACR Special Conference on Pancreatic Cancer Research.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.